瑞格列奈+二甲双胍治疗2型糖尿病的疗效及血糖水平改善分析  

Analysis of the Effect of Repaglinide+Metformin in the Treatment of Type 2 Diabetes Mellitus and the Improvement of Blood Glucose Level

作　　者：周文恒 李芳芳 ZHOU Wenheng;LI Fangfang(General Department,Jinan Seventh People's Hospital Community Health Service Center,Jinan 250100,Shandong,China)

机构地区：[1]济南市第七人民医院社区卫生服务中心全科,山东济南250100

出　　处：《糖尿病新世界》2025年第3期70-73,共4页Diabetes New World

摘　　要：目的分析瑞格列奈+二甲双胍治疗2型糖尿病的疗效。方法选取2023年1月-2024年5月济南市第七人民医院社区卫生服务中心的96例2型糖尿病患者,按不同的治疗方案为A、B两组,每组48例。A组应用二甲双胍治疗,B组在A组的基础上联合应用瑞格列奈。比较两组治疗效果、治疗前后血糖水平、血糖波动幅度及安全性。结果B组治疗总有效率、不良反应发生率较A组高,平均血糖波动幅度、最大血糖波动幅度水平较A组低,差异均有统计学意义(P均<0.05)。治疗后,组间空腹血糖、糖化血红蛋白水平对比,B组更低,差异均有统计学意义(P均<0.05)。结论采用瑞格列奈+二甲双胍治疗2型糖尿病,可提升治疗效果,降低患者血糖水平,并减少血糖波动,但会增加治疗不良反应。Objective To analyze the efficacy of repaglinide+metformin in the treatment of type 2 diabetes mellitus.Methods From January 2023 to May 2024,96 patients with type 2 diabetes mellitus were selected from Jinan Seventh People's Hospital Community Health Service Center.According to different treatment schemes,they were divided into group A and group B,with 48 cases in each group.Group A was treated with metformin,and group B was treated with repaglinide on the basis of group A.The therapeutic effect,blood glucose levels before and after treatment,blood glu-cose fluctuation range and safety were compared between the two groups.Results The total effective rate of treatment and incidence of adverse reactions in group B were higher than those in group A,and the mean and maximum fluctua-tion ranges of blood glucose were lower than those in group A,the differences were statistically significant(all P<0.05).After treatment,the fasting plasma glucose and glycated hemoglobin A1c in the two groups were compared,and those in group B were lower,the differences were statistically significant(both P<0.05).Conclusions The use of repa-glinide+metformin in the treatment of type 2 diabetes mellitus can improve the therapeutic effect,reduce the blood glucose level of patients,and reduce blood glucose fluctuations,but it will increase the adverse reactions of treatment.

关 键 词：2型糖尿病 二甲双胍 瑞格列奈 

分 类 号：R587[医药卫生—内分泌]